Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNAseq of CCRF-CEM, a T-cell acute lymphoblastic leukemia cell line, after knockdown with 2 control hairpins and 6 hairpins targeting the PRC2 complex.

ABSTRACT: The data was used to study mechanisms of apoptosis resistance induced by loss of PRC2.

ORGANISM(S): Homo sapiens

PROVIDER: GSE95648 | GEO | 2018/03/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Identification of PRC2 complex interactor

Project description:Affinity capture of PRC2 complex and its reader protein BP1

2021-08-26 | PXD028134 |

Identification of the novel interacting partners of the mammalian target of rapamycin complex 1 in human CCRF-CEM and HEK293 cells.

Project description: Not available

| S-EPMC3975426 | biostudies-literature

Bortezomib resistance in CCRF-CEM cell line

Project description:This SuperSeries is composed of the SubSeries listed below.

2015-11-04 | GSE74635 | GEO

Bortezomib resistance in CCRF-CEM cell line

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-11-04 | E-GEOD-74635 | biostudies-arrayexpress

Dual Mechanisms of Metabolism and Gene Expression of the CCRF-CEM Leukemia Cells under Glucocorticoid Treatment.

Project description: Not available

| S-EPMC8198442 | biostudies-literature

Bortezomib resistance in CCRF-CEM cell line [miRNA]

Project description:Bortezomib is a proteasome inhibitor used in severel different hematological malignancies. Resistance to this drug is still poorly understood. In order get more insight in the resistance mechanism, we developed several bortezomib resistant subclones of the CCRF-CEM T-ALL cell line. On these subclones comparative Genome hybridization (arrayCGH) for DNA copy number analysis gene expression and micro-RNA expression arrays were performed.

2015-11-04 | GSE74632 | GEO

Bortezomib resistance in CCRF-CEM cell line [GEP]

2015-11-04 | GSE74634 | GEO

Bortezomib resistance in CCRF-CEM cell line [CGH]

2015-11-04 | GSE74633 | GEO

Genomic and transcriptomic profiling of resistant CEM/ADR-5000 and sensitive CCRF-CEM leukaemia cells for unravelling the full complexity of multi-factorial multidrug resistance.

Project description: Not available

| S-EPMC5099876 | biostudies-literature

CCRF-CEM Prednisolone treatment at 4h

Project description:Background: Glucocorticoids are important pharmaceutical agents in the treatment of acute lymphoblastic leukemia in children. Resistance or sensitivity to glucocorticoids is considered to be of crucial importance for disease prognosis. Prednisolone is a first-line chemotherapeutic agent in the treatment of acute lymphoblastic leukemia. Here, the effects of prednisolone on the resistant CCRF-CEM leukemic cell line were studied. Methods: Prednisolone’s cytotoxic and cell cycle effects were studied with flow cytometry. NF-κB translocation was studied with Western Blotting and differential gene expression was studied with cDNA microarrays. Results: Prednisolone exerted a delayed biphasic effect, necrotic at low doses and apoptotic at higher doses. At low doses, prednisolone exerted a pre-dominant mitogenic effect despite its induction on total cell death, while at higher doses, prednisolone’s mitogenic and cell death effects were counterbalanced. NF-κB was constitutively present in the nucleus. Early gene microarray analysis revealed 40 differentially expressed genes upon 4 hours of prednisolone’s exposure. Notable differences in gene regulation were observed between the lowest and the highest glucocorticoid doses. Prednisolone activated genes related to apoptosis/tumor suppression, cell cycle progression, metabolism and intra-/ extra-cellular signaling pathways. Conclusions: The mitogenic/biphasic effects of prednisolone are of clinical importance in the case of resistant leukemic cells. This approach might lead to the identification of gene candidates for future molecular drug targets in combination therapy with glucocorticoids, along with early markers for glucocorticoid resistance.

2011-03-22 | GSE27989 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data